Vaccine development can be really expensive, and there’s limited commercial return.

Vaccine development can be really expensive, and there’s limited commercial return.

When it comes to Ebola outbreaks, it's not often we have two pieces of good news in one week.

Contro il virus responsabile dell'attuale epidemia africana non disponiamo ancora di un vaccino approvato. Ecco le criticità attuali e quali strategie vengono …